title: Technology evaluation: NeuroVax, Immune Response Corp.
abstract: The Immune Response Corp is developing NeuroVax, a combination vaccine of three T-cell receptor peptides (BV5S2, BV6S5 and BV13S1) in incomplete Freund's adjuvant, as a potential treatment for multiple sclerosis. The vaccine is currently undergoing phase II clinical trials.
authors.affiliation: University of Otago Medical School, Department of Pharmacology and Toxicology, Dunedin, New Zealand. cynthia.darlington@stonebow.otago.ac.nz
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Darlington
mesh_terms: D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D006801:Humans; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy*; D010330:Patents as Topic; D014612:Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D014612:Vaccines